- 4-Week # shares sold: 2,500
- 12-Week # shares sold: 8,124
- 24-Week # shares sold: 48,713
The firm received a "refusal to file letter" from the FDA regarding the new drug application for Inbrija, a potential treatment for Parkinson's disease.
The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.
David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.
ChemoCentryx, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Zogenix were among the biotech stock movers in premarket trading Friday.